KRT16 (Keratin 16)

Beyond oncology, mutations in KRT6A underlie pachyonychia congenita, and its dysregulation contributes to epidermal hyperproliferative disorders such as psoriasis. Overall, systematic elucidation of the structure-function-pathway-clinical axis of KRT6A offers new opportunities for precision medicine and supports its potential as a therapeutic target in cancer management.

Functional assays using IL13RA1 and IL4R knockdown confirmed that IL-13 signaling promotes keratinocyte proliferation and migration. These findings define a key immunoregulatory pathway linking epithelial transformation and immune interaction, providing a cellular framework for understanding early cSCC development and identifying potential targets for intervention.

Furthermore, high MAPK10 expression was associated with a favorable prognosis in NSCLC patients, as evidenced by a hazard ratio (HR) of 0.42 (95 % confidence interval: 0.28-0.63). Collectively, these findings establish the MAPK10/KRT16/RNF213 axis as a promising therapeutic target and prognostic biomarker for NSCLC metastasis, providing new directions for the development of personalized treatment strategies.

This study established the first comprehensive spatial transcriptomic atlas of cervical cancer, revealing unprecedented insights into tumor microenvironment organization and cellular spatial relationships.

Finally, in vitro experiments showed that the viability, migration, and invasion of OSCC cells were markedly suppressed after knockdown of KRT16. Our study provided novel biomarkers targeting keratinocytes for the treatment of OSCC.

The dressing preserved structural integrity, demonstrated favorable cytocompatibility, and modulated key inflammatory and regenerative pathways. These findings underscore the translational potential of FKDP+0.1%Act as a dual-functional biomaterial capable of enhancing epithelial regeneration and reprogramming inflammatory responses in impaired diabetic wound environments.

These findings offer novel insights into resistance mechanisms and propose actionable strategies for integrating targeted and immunotherapies to improve outcomes for NSCLC patients. Future experimental and clinical studies are essential to validate and translate these findings into therapeutic advances.

This integrative transcriptomic and machine learning framework effectively identified high-confidence biomarkers for GC. Notably, CST1, TIMP1, KRT16, and ATP4A emerged as consistent, biologically relevant candidates with strong diagnostic performance and potential clinical utility. These findings may aid early detection strategies and guide future therapeutic developments in gastric cancer.

The results provide novel insights into prognosis prediction and therapeutic responses, and identify VSIG4 and STAB1 as potential biomarkers affecting macrophages in HGSOC.

In conclusion, we identified four key genes-SERPINE2, DPYSL3, CTSE, and KRT16-that can be used to develop a prognostic model for bladder cancer. These findings may provide valuable molecular targets for the clinical diagnosis and therapeutic strategies of bladder cancer.

Berberine demonstrates multi-target therapeutic potential in managing RISI by modulating inflammation, oxidative stress, and cellular repair processes. These findings provide a foundation for future clinical studies to optimize its dosage and delivery, aiming to improve treatment outcomes for RISI.

We have elucidated key genes and molecular mechanisms linked to NSCLC subtypes. These findings have the potential to facilitate improved diagnostic and therapeutic targets for LUAD and LUSC biomarkers.